Announcements Trials
Browse Landscape

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 119Observational 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 112Neoplasms 73Carcinoma, Non-Small-Cell Lung 36Carcinoma, Renal Cell 35Prostatic Neoplasms 34Colorectal Neoplasms 34Lung Neoplasms 31Melanoma 17Multiple Myeloma 15Ovarian Neoplasms 13Urinary Bladder Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 11Lymphoma, Follicular 11Colonic Neoplasms 11Stomach Neoplasms 10Lymphoma 10Kidney Neoplasms 10Hematologic Neoplasms 10Rectal Neoplasms 9Arthritis, Rheumatoid 9Recurrence 8Papillomavirus Infections 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Pancreatic Neoplasms 7Neoplasms, Plasma Cell 7Lymphoma, Large B-Cell, Diffuse 7COVID-19 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

lorlatinib 1dinutuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Has results × Neuroblastoma × Clear all
NCT04753658 2024-09-23

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Pfizer

Terminated
15 enrolled 22 charts
CNS

Neuroblastoma

NCT02693171 2019-08-05

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

United Therapeutics

Terminated
13 enrolled 9 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡